Clinical Trials
Clinical trials are the rigorous, scientific studies of new drugs in development. They are administered in a carefully controlled process by which patients’ rights and well-being are always paramount. Every new drug has to go through the clinical trial process before it is FDA approved, including all the “miracle drugs” of the last decade (such as Gleevec®, Rituxan®, and Herceptin®.
Clinical Trials for Cancer
Breast Cancer Clinical Trials
- A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3
Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast
Cancer at High Risk of Recurrence (D-CARE) (20060359)
Phase III
For more information call (310)205-5707 or email us
Lung Cancer - Non Small Cell (NSCLC) Clinical Trials
- Phase 3, Randomized, Open-label Study of the Efficacy and Safety of Crizotinib vs Pemetrexed/Cisplatin or Pemetrexed/carboplatin in Previoulsy Untreated Patients with NSCLC Harboring a Translocation or Inversion Event Involving the Anaplastic Lymphoma Kinase (ALK) Gene Locus (A8081014)
Click Here for Full Protocol and Eligibility Criteria
Phase II
For more information call (310)205-5707 or email us - A Phase I/II Maximum Tolerated Dose Study of Belinostat (PXD-101) in Combination with Paclitaxel plus Carboplatin in Chemotherapy-Naive Patients with Stage IV Non-Small-Cell Lung Cancer (NSCLC).SPI-1014-Bel
Phase I/II
For more information call (310)205-5707 or email us
Lymphoma: Non-Hodgkin Clinical Trials
- An Open-Label, Dose-Escalation Phase 1 Study of MLN9708, A Second-Generation Proteasome Inhibitor, in Adult Patients with Lymphoma (C16002)
Click Here for Full Protocol and Eligibility Criteria
Phase I
For more information call (310)205-5707 or email us - A Phase II, Multicenter, Single-Arm, Open-Label Study of Single-Agent Lenalidomide (Revlimid) in Patients with Mantle Cell non-Hodgkins Lymphoma who have relapsed after Bortezomib or are Refractory or Intolerant to Bortezmib (CC-5013-MCL-001)
Click Here for Full Protocol and Eligibility Criteria
Phase II
For more information call (310)205-5707 or email us - An Open-Label, Randomized, Phase 2 Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Patients with Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma (C05013)
Click Here for Full Protocol and Eligibility Criteria
Phase II
For more information call (310)205-5707 or email us - A Phase 2, Singleparm, Open-label, Multi-center Study of Pralatrexate in Patients with Aggressive Relapsed B-cell Non-Hodgkin's Lymphoma (PDX-015)
Click Here for Full Protocol and Eligibility Criteria
Phase II
For more information call (310)205-5707 or email us - Phase 2 Trial of MLN8237, and Oral Aurora Kinase Inhibitor, In Adult Patients with Aggressive Non-Hodgkin's Lymphoma (C14004)
Click Here for Full Protocol and Eligibility Criteria
Phase II
For more information call (310)205-5707 or email us
Multisite Advanced Cancers (Phase I/II) Clinical Trials
- A Phase I Dose-Escalation Study of PHA-739358 Administered in Combination with Docetaxel or Gemcitabine or Bevacizumab in Adult Patients with Advanced Solid Tumors. (AURA-6202-008)
Phase I
For more information call (310)205-5707 or email us - A Phase 1, First-in-Human Study evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 208 in Adult Subjects with Advanced Solid Tumors (AMG 208 20080895)
Click Here for Full Protocol and Eligibility Criteria
Phase I
For more information call (310)205-5707 or email us - A Phase I Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients with Nonhematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies
Click Here for Full Protocol and Eligibility Criteria
Phase II
For more information call (310)205-5707 or email us - A Phase 1 Dose Escalation Study To Determine The Safety, Pharmacokinetics And Pharmacodynamics Of Intravenous TKM-080301 In Patients With Advanced Solid Tumors (TKM-PLK1-001)
Phase I
For more information call (310)205-5707 or email us - A Phase Ib, Single-arm, Open-Label Clinical trial to Evauate Corrected QT interval and Drug-Drug-Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients with Her2-positive Metastatic or Locally Advanced Inoperable Cancer (H4613g)
Phase IB
For more information call (310)205-5707 or email us
Myeloma Clinical Trials
- Expanded Access Carfilzomib (C-MAP)
Phase IV
For more information call (310)205-5705 or email us
Myeloproliferative Disease Trials
- An Open Label Assessment Of Safety And Efficacy Of Ruxolitinib (INCB018424) In Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-Myelofibrosis And Post Polycythemia Vera-Myelofibrosis Who Have Platelet Counts Of 50 X109/L to 100 x109/L (INCB18424-258)
Phase III
For more information call (310)205-5705 or email us
Pancreatic Cancer Clinical Trials
- A Randomized Phase III Study of Weekly ABI-007 plus Gemcitabine versus Gemcitabine Alone in Patients with Metastatic Adenocarcinoma of the Pancreas(CA046)
Click Here for Full Protocol and Eligibility Criteria
Phase III
For more information call (310)205-5707 or email us
Treatments for Genetic Disorders
Gaucher
- A Phase 3, Randomized, Multi-Center, Multi-National, Open-Label, Active Comparator Study to Evaluate the Efficacy and Safety of Genz-112638 in Patients with Gaucher Disease Type 1 who have been Stabilized with Cerezyme. (GZGD02607)
Click Here for Full Protocol and Eligibility Criteria
Phase III
For more information call (310)205-5707 or email us - A Phase 3, Randomized, Multi-Center, Multi-National, Open-Label, Active Comparator Study to Evaluate the Efficacy and Safety of Genz-112638 in Patients with Gaucher Disease Type 1 who are newly diagnosed (GZGD02507) ENGAGE
For more information call (310)205-5707 or email us